➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Mallinckrodt
Dow
Express Scripts
McKesson

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Litigation Details for Facebook, Inc. v. BlackBerry Limited (N.D. Cal. 2018)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Facebook, Inc. v. BlackBerry Limited (N.D. Cal. 2018)

Docket   Start Trial Date Filed 2018-09-04
Court District Court, N.D. California Date Terminated
Cause 35:271 Patent Infringement Assigned To Jeffrey Steven White
Jury Demand Both Referred To
Parties BLACKBERRY CORPORATION; BLACKBERRY LIMITED; FACEBOOK, INC.
Patents 10,011,843; 10,016,429; 10,022,606; 10,023,841; 10,034,841; 10,035,843; 10,071,284; 10,072,053; 10,105,415; 10,105,418; 10,117,844; 10,213,415; 10,259,841; 10,261,091; 10,284,108; 10,314,896; 10,315,091; 10,415,014; 10,532,091; 10,556,037; 10,597,432; 6,020,001; 6,121,021; 6,121,027; 6,231,849; 6,302,556; 6,693,115; 6,759,079; 7,009,037; 7,041,302; 7,087,432; 7,090,830; 7,105,314; 7,105,530; 7,154,029; 7,443,135; 7,575,742; 7,651,698; 7,749,532; 7,759,079; 7,759,128; 7,896,759; 8,006,698; 8,021,443; 8,021,693; 8,021,875; 8,071,556; 8,101,429; 8,101,575; 8,110,606; 8,119,134; 8,119,418; 8,299,057; 8,314,117; 8,501,164; 8,501,698; 8,575,164; 8,759,284; 8,759,616; 8,841,087; 8,841,125; 8,843,356; 8,865,443; 8,865,698; 8,896,843; 9,005,616; 9,012,606; 9,023,616; 9,023,843; 9,029,356; 9,072,744; 9,072,759; 9,079,865; 9,108,002; 9,108,015; 9,120,744; 9,134,299; 9,213,038; 9,284,314; 9,284,315; 9,284,556; 9,415,016; 9,415,025; 9,415,029; 9,415,050; 9,415,053; 9,415,284; 9,555,079; 9,556,261; 9,567,356; 9,575,072; 9,616,024; 9,616,028; 9,616,031; 9,616,049; 9,616,059; 9,616,090; 9,616,105; 9,616,121; 9,650,433; 9,744,105; 9,744,302; 9,841,001; 9,844,567; 9,849,164; 9,896,698
Attorneys Benjamin S. Lin; Brian Charles Riopelle; Cameron Cortez Vanderwall; Edward Robert McGah , Jr.; Heidi Lyn Keefe; Ian Scott Shelton; Iman Lordgooei; James Robert Asperger; Jonathan Sze Ming Tse; Jordan Ross Jaffe; Kevin P.B. Johnson; Lowell D. Mead; Mark Anthony Zambarda; Mark R. Weinstein; Matthew David Caplan; Matthew J. Brigham; Michael Anthony Parks; Michael Graham Rhodes; Pushkal Mishra; Sartouk H Moussavi; Victoria F. Maroulis; Yury Kapgan
Firms Brian Charles Riopelle ,; Cooley LLP; Eversheds Sutherland (US) LLP; Quinn Emanuel; Quinn Emanuel Urquhart & Sullivan LLP; Quinn Emanuel Urquhart & Sullivan, LLP; Quinn Emanuel Urquhart and Sullivan LLP; Quinn Emanuel Urquhart Oliver & Hedges L; Thompson Coburn LLP; Verizon Wireless, E305
Link to Docket External link to docket

Details for Facebook, Inc. v. BlackBerry Limited (N.D. Cal. 2018)

Date Filed Document No. Description Snippet Link To Document
2020-01-10 100 Opposition/Response to Motion -05434-JSW Document 100 Filed 01/10/20 Page 6 of 20 1 On January 8, 2019, Facebook served its infringement… 26 patents including U.S. Patent Nos. 7,228,432 (“’432 Patent”) and 7,302,698 (“’698 Patent”). (Dkt…between these U.S. patents and the asserted patent claims made 14 these patents eminently easy to find…references are U.S. patents that use the same relevant terminology as the asserted ’698 18 Patent claims. BlackBerry…2 claim 1 of the ’432 Patent and asserted dependent claims 3-6. (’432 Patent, claims 1 and 3-6.) 3 External link to document
2020-05-01 119 Stay covenant not to sue on the ’759 and ’698 Patents (Dkt. 117). However, 25 the covenant does not divest…the “Patents-in-Suit”). The instituted IPRs are directed to all of the asserted claims 10 from the ’759…review (“IPR”) 10 proceedings against every asserted claim of the ’698 and ’759 Patents.1 Additionally… Patent-in-Suit PTO/PTAB Control No. Challenged Claims 10 … ’759 Patent IPR2019-01597 1, 4-6, 8-10 (all asserted claims) 11 External link to document
2020-05-15 120 Notice (Other) 94111 6 Telephone: (213) 443-3000 Telephone: (415) 875-6600 7 Facsimile: (213) 443-3100 …Telephone: (213) 443-3000 Facsimile: (213) 443-3100 … Telephone: 415-875-6600 19 Facsimile: 415-875-6700 20… Facsimile: (415) 875-6700 8 Kevin P.B. Johnson (Bar No. 177129) kevinjohnson@quinnemanuel.com…Limited regarding ex parte reexamination of '575 Patent (Attachments: # 1 Exhibit A)(Lordgooei, Iman) ( External link to document
2020-05-16 121 Opposition/Response to Motion Facebook 11 and all successors and assigns1) that its covenant not to sue as to those patents extends… a reasonable examiner in deciding patentability.” (Id. at 5, 9, 11, 12.) The decision does not state …before its one-year bar 11 to file IPR petitions on the four remaining patents, and then waited more …759 and ’698 Patents. ............................................................... 4 10 …BlackBerry sought reconsideration only as to the ’841 patent, 10 which the PTAB promptly denied. The 30-day External link to document
2020-05-22 122 Reply to Opposition/Response claims of the patents-in-suit. 8 Additionally, with respect to the ’841 Patent, although the…invalidation of at least claims 12, 15, and 16 of the ’841 Patent. 13 Furthermore, despite Facebook’s…REEXAMINATION AND INTER 23 PARTES REVIEW OF PATENTS-IN- …[challenger’s] 23 petitions for inter partes review regarding [the] asserted patents”). 24 1 …little brother” computing entity, because the 23 ’698 Patent’s “monitoring component” requires “determin External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
AstraZeneca
Moodys
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.